MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer

Mark Bloomston, Alexis Shafii, Emmanuel E. Zervos, Amyn Mohammed Rojiani, Alexander S. Rosemurgy

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction. Genetic therapy aimed at disturbing the balance between matrix metalloproteinases (MMP) and their natural tissue inhibitors (TIMP) in treatment of pancreatic cancer requires an understanding of whether MMP and TIMP are tumor- or host-derived. This study was undertaken to determine whether production of MMP-2 and TIMP-1 is by, or in response to, pancreatic cancer. Methods. PANC-1 (poorly differentiated human pancreatic cancer) or CD-1 (PANC cells transfected to overproduce TIMP-1) cells were implanted into the pancreata of 20 nude mice. After sacrifice, tumors and peritumoral stroma underwent immunohistochemical staining for human and murine MMP-2 and TIMP-1. Normal murine pancreas served as control. All stains were reviewed in a "blinded" manner by a pathologist and graded relative to normal control pancreata. Results. Control pancreata displayed faint murine MMP-2 and TIMP-1 staining and no human MMP-2 or TIMP-1. MMP-2 was most prominent in peritumoral stroma, while TIMP-1 was most prominent in tumors. CD-1 tumors contained very high levels of TIMP-1 compared to PANC-1 tumors and control pancreata. Tumoral and peritumoral MMP-2 were overwhelmingly human. As well, tumoral TIMP-1 was predominantly human. Conclusions. In a murine model for human pancreatic cancer, nearly all TIMP-1 and MMP-2 expression is tumor-derived (i.e., human). Pharmacologic and gene therapy aimed at disturbing the MMP/TIMP balance in pancreatic cancer should be targeted toward tumor-specific mechanisms and warrants continued investigation.

Original languageEnglish (US)
Pages (from-to)35-38
Number of pages4
JournalJournal of Surgical Research
Volume102
Issue number1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase 2
Pancreatic Neoplasms
Pancreas
Matrix Metalloproteinases
Neoplasms
Genetic Therapy
Staining and Labeling
Nude Mice

ASJC Scopus subject areas

  • Surgery

Cite this

MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. / Bloomston, Mark; Shafii, Alexis; Zervos, Emmanuel E.; Rojiani, Amyn Mohammed; Rosemurgy, Alexander S.

In: Journal of Surgical Research, Vol. 102, No. 1, 01.01.2002, p. 35-38.

Research output: Contribution to journalArticle

Bloomston, Mark ; Shafii, Alexis ; Zervos, Emmanuel E. ; Rojiani, Amyn Mohammed ; Rosemurgy, Alexander S. / MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. In: Journal of Surgical Research. 2002 ; Vol. 102, No. 1. pp. 35-38.
@article{9a69866a2e0942c08b7accb9cbcd795e,
title = "MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer",
abstract = "Introduction. Genetic therapy aimed at disturbing the balance between matrix metalloproteinases (MMP) and their natural tissue inhibitors (TIMP) in treatment of pancreatic cancer requires an understanding of whether MMP and TIMP are tumor- or host-derived. This study was undertaken to determine whether production of MMP-2 and TIMP-1 is by, or in response to, pancreatic cancer. Methods. PANC-1 (poorly differentiated human pancreatic cancer) or CD-1 (PANC cells transfected to overproduce TIMP-1) cells were implanted into the pancreata of 20 nude mice. After sacrifice, tumors and peritumoral stroma underwent immunohistochemical staining for human and murine MMP-2 and TIMP-1. Normal murine pancreas served as control. All stains were reviewed in a {"}blinded{"} manner by a pathologist and graded relative to normal control pancreata. Results. Control pancreata displayed faint murine MMP-2 and TIMP-1 staining and no human MMP-2 or TIMP-1. MMP-2 was most prominent in peritumoral stroma, while TIMP-1 was most prominent in tumors. CD-1 tumors contained very high levels of TIMP-1 compared to PANC-1 tumors and control pancreata. Tumoral and peritumoral MMP-2 were overwhelmingly human. As well, tumoral TIMP-1 was predominantly human. Conclusions. In a murine model for human pancreatic cancer, nearly all TIMP-1 and MMP-2 expression is tumor-derived (i.e., human). Pharmacologic and gene therapy aimed at disturbing the MMP/TIMP balance in pancreatic cancer should be targeted toward tumor-specific mechanisms and warrants continued investigation.",
author = "Mark Bloomston and Alexis Shafii and Zervos, {Emmanuel E.} and Rojiani, {Amyn Mohammed} and Rosemurgy, {Alexander S.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1006/jsre.2001.6317",
language = "English (US)",
volume = "102",
pages = "35--38",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer

AU - Bloomston, Mark

AU - Shafii, Alexis

AU - Zervos, Emmanuel E.

AU - Rojiani, Amyn Mohammed

AU - Rosemurgy, Alexander S.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Introduction. Genetic therapy aimed at disturbing the balance between matrix metalloproteinases (MMP) and their natural tissue inhibitors (TIMP) in treatment of pancreatic cancer requires an understanding of whether MMP and TIMP are tumor- or host-derived. This study was undertaken to determine whether production of MMP-2 and TIMP-1 is by, or in response to, pancreatic cancer. Methods. PANC-1 (poorly differentiated human pancreatic cancer) or CD-1 (PANC cells transfected to overproduce TIMP-1) cells were implanted into the pancreata of 20 nude mice. After sacrifice, tumors and peritumoral stroma underwent immunohistochemical staining for human and murine MMP-2 and TIMP-1. Normal murine pancreas served as control. All stains were reviewed in a "blinded" manner by a pathologist and graded relative to normal control pancreata. Results. Control pancreata displayed faint murine MMP-2 and TIMP-1 staining and no human MMP-2 or TIMP-1. MMP-2 was most prominent in peritumoral stroma, while TIMP-1 was most prominent in tumors. CD-1 tumors contained very high levels of TIMP-1 compared to PANC-1 tumors and control pancreata. Tumoral and peritumoral MMP-2 were overwhelmingly human. As well, tumoral TIMP-1 was predominantly human. Conclusions. In a murine model for human pancreatic cancer, nearly all TIMP-1 and MMP-2 expression is tumor-derived (i.e., human). Pharmacologic and gene therapy aimed at disturbing the MMP/TIMP balance in pancreatic cancer should be targeted toward tumor-specific mechanisms and warrants continued investigation.

AB - Introduction. Genetic therapy aimed at disturbing the balance between matrix metalloproteinases (MMP) and their natural tissue inhibitors (TIMP) in treatment of pancreatic cancer requires an understanding of whether MMP and TIMP are tumor- or host-derived. This study was undertaken to determine whether production of MMP-2 and TIMP-1 is by, or in response to, pancreatic cancer. Methods. PANC-1 (poorly differentiated human pancreatic cancer) or CD-1 (PANC cells transfected to overproduce TIMP-1) cells were implanted into the pancreata of 20 nude mice. After sacrifice, tumors and peritumoral stroma underwent immunohistochemical staining for human and murine MMP-2 and TIMP-1. Normal murine pancreas served as control. All stains were reviewed in a "blinded" manner by a pathologist and graded relative to normal control pancreata. Results. Control pancreata displayed faint murine MMP-2 and TIMP-1 staining and no human MMP-2 or TIMP-1. MMP-2 was most prominent in peritumoral stroma, while TIMP-1 was most prominent in tumors. CD-1 tumors contained very high levels of TIMP-1 compared to PANC-1 tumors and control pancreata. Tumoral and peritumoral MMP-2 were overwhelmingly human. As well, tumoral TIMP-1 was predominantly human. Conclusions. In a murine model for human pancreatic cancer, nearly all TIMP-1 and MMP-2 expression is tumor-derived (i.e., human). Pharmacologic and gene therapy aimed at disturbing the MMP/TIMP balance in pancreatic cancer should be targeted toward tumor-specific mechanisms and warrants continued investigation.

UR - http://www.scopus.com/inward/record.url?scp=0036350763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036350763&partnerID=8YFLogxK

U2 - 10.1006/jsre.2001.6317

DO - 10.1006/jsre.2001.6317

M3 - Article

VL - 102

SP - 35

EP - 38

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -